Array Biopharma Inc (NASDAQ:ARRY) a biopharmaceutical firm focused on the development, commercialization and discovery of targeted small molecule cancer treatments reported financial results for 2Q2017 and released an update on the development of its major clinical development plans. Ron Squarer, the CEO, reported that they are delighted to announce that...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Jaguar Animal Health Inc (NASDAQ:JAGX) has announced the signing of a distribution agreement, with JP Equine Services. The agreement would cover two non-prescription products from the company and would be distributed in Japan. Neonorm Foal and Neonorm Calf, the products in question, are natural, clinically tested, non-drug products that...
Although a tremendous progress has been made, large full-thickness skin defects are still associated with mortality due to a low availability of donor skin areas. Autologous cultured epidermal autografts (CEA) were first to be used as an epidermal substitute; however, their functional and esthetic results were unsatisfying due to graft...
Gilead Sciences, Inc. (NASDAQ:GILD) hasn’t been able to bring a smile on the investors’ faces throughout the first three quarters of 2016, and in the last quarter as well, the company did not break the ice. Following the downward trend, the company announced its Q4 2016 results recently, and...
Exelixis, Inc. (NASDAQ:EXEL) has released their financials results for the 4Q2016 and FY2016. The company also provided an update on its corporate objectives and upcoming milestones. For its 4Q2016, EXEL recorded a net income of $35.1 million, as compared to a net loss for 4Q2015. Exelixis was able to...
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) recently announced that it would be exercising a 1-for-10 reverse stock split, of all outstanding shares of the company’s common stock. Moreover, RNN would also exercise a corresponding proportional reduction in the number of authorized capital shares of the company, as well. The action is...
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stated that, subsequent to an autonomous DSMB recommendation and also following futility assessment, it has halted the Phase II HERMIONE trial of “MM-302” in people suffering with +HER2 metastatic breast cancer, but had initially been on regimen of pertuzumab, trastuzumab and ado-trastuzumab emtansine. The buzz The decision...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Heat Biologics Inc (NASDAQ:HTBX) recently said that the survival results and top-line response of Phase 1b study evaluating lung cancer treatment with Bristol-Myers Squibb’s drug showed positive signs. The company reported HS-110/Nivolumab Combination for treating non-small cell lung cancer (NSCLC) in Austria at International Association for the Study of...